Development of a novel transcutaneous delivery peptide and its application in skin inflammation (HYP7P.273)

Abstract

Abstract Transcutaneous delivery of therapeutic drugs has many advantages over the systemic administration for inflammatory skin diseases such as atopic dermatitis or psoriasis. However, the greatest challenge for transcutaneous delivery is methodology due to the tight junction of skin tissue. Here, we screened and identified transdermal delivery peptide (TDP) from human proteins which would be non-invasive and simple method to deliver various cargos such as chemicals, peptides, proteins, etc. TDP-EGFP recombinant protein was purified and exhibited significantly higher intracellular transduction efficacy compared with TAT-EGFP in Jurkat, HaCaT, NIH3T3 cell lines and also in primary cells including splenocytes and keratinocytes. TDP-TAMRA peptides were successfully delivered into the epidermis and dermis of the mouse ear and back skin. We also used TDP-VIVIT peptide to inhibit T cell activation and contact dermatitis in vivo. TDP-VIVIT significantly inhibited IL-2 secretion with reduction of CD69 and CD44 expression level of activated CD4 and CD8 T cells. Our results suggest TDP-VIVIT peptide could be a potential transdermal applicable therapeutic drug for inflammatory skin diseases.